|
|
|
|
Belite Bio Inc (NASDAQ: BLTE) |
|
Price: $65.2100
$0.71 
1.101%
|
| Day's High:
| $66.58
| Week Perf:
| -3.72 %
|
| Day's Low: |
$ 64.30 |
30 Day Perf: |
16.34 % |
| Volume (M): |
22 |
52 Wk High: |
$ 86.53 |
| Volume (M$): |
$ 1,428 |
52 Wk Avg: |
$54.03 |
| Open: |
$66.58 |
52 Wk Low: |
$31.01 |
|
|
| Market Capitalization (Millions $) |
1,991 |
| Shares
Outstanding (Millions) |
31 |
| Employees |
60 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-36 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Belite Bio Inc
Company Address: 12750 High Bluff Drive Suite 475, San Diego 92130 CA
Company Phone Number: 246-6240 Stock Exchange / Ticker: NASDAQ BLTE
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Stock Market Announcement
Published Thu, Feb 6 2025 3:35 AM UTC
Belite Bio Secures $15 Million in Direct Offering Amidst Market FluctuationsSAN DIEGO On February 5, 2025, Belite Bio, Inc. (Nasdaq: BLTE), a clinical-stage biopharmaceutical company specializing in developing therapies for degenerative retinal diseases, announced a registered direct offering of approximately $15 million. This strategic move comes as the company seeks to bol...
|
| Product Service News
Published Tue, Sep 10 2024 12:01 PM UTC
The development of novel therapeutics for retinal diseases represents a significant frontier in pharmaceutical innovation, especially for conditions like Stargardt Disease (STGD1), which currently lacks effective treatment options. Belite Bio, Inc., a clinical-stage biopharmaceutical company based in San Diego, is at the forefront of this endeavor with its recent announcemen...
|
| Licensing Agreement
Published Wed, Jun 12 2024 6:56 AM UTC
Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical company specializing in novel therapies for degenerative retinal diseases, has achieved a significant milestone. On June 12, 2024, the company announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Sakigake (Pioneer Drug) Designation to its lead therapeutic candidate, Tinlareban...
|
| Clinical Study
Published Mon, May 6 2024 12:01 PM UTC
San Diego-based biopharmaceutical firm, Belite Bio, Inc., revealed further key results from its 24-month Phase 2 study of the drug Tinlarebant, which is targeted at treating Stargardt Disease. This announcement took place at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) on May 06, 2024.A trailblazer in the development of innovative tre...
|
| Contract
Published Thu, Apr 25 2024 11:15 PM UTC
San Diego-based clinical-stage biopharmaceutical drug development company, Belite Bio, Inc (NASDAQ: BLTE), has taken a significant step forward in its fight against degenerative retinal diseases, announcing on April 25, 2024, that it has negotiated a securities purchase agreement with an institutional investor for a registered direct offering. The focus of Belite Bio has al...
|
| Per Share |
Current |
| Earnings (TTM) |
-1.18 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
1.19 $
|
| Book Value |
4.78 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.18 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
1.19 $
|
| Book Value |
4.78 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
